September 1, 2025 · Form 4 insider transaction
Moat Ross bought 9,828 shares of Kiniksa Pharmaceuticals Ltd. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 2 days after the transaction.
Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.; The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2025.